炎症因子评分对晚期非小细胞肺癌患者预后评估的应用价值

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (706 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To evaluate the value of inflammatory factor score in prognosis of advanced nonsmall cell lung cancer(NSCLC). Methods: The clinical data of 156 patients with advanced NSCLC were collected. The modified Glasgow prognostic score(mGPS), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were tested. The mGPS was divided into 0, 1, 2 groups based on Creactive protein and albumin. The NLR and PLR were divided into low score groups and high score groups with median as the optimal cutoff value, respectively. The relationship between the inflammatory index and the clinical features, chemotherapy efficacy and progressionfree survival(PFS) were analyzed. The prognostic factors of age, gender, tumor markers, pathological types, distant metastasis, mGPS, NLR, PLR and white blood cells were evaluated by univariate and multivariate regression analysis. Results: The objective response rate(ORR) of mGPS 0 group was higher than that of mGPS 1 group and mGPS 2 group(P＜0.05). The ORR of low NLR group was higher than that of high NLR group(P＜0.05). There was no statistical difference between PLR groups(P>0.05). The disease control rate of mGPS 0 group was higher than that of mGPS 1 group and mGPS 2 group, low NLR group was higher than that of high NLR group, and low PLR group was higher than that of high PLR group(P＜0.05). Between the three groups of mGPS0, 1 and 2, the PFS was longer in the low score group than that in the high score group (P＜0.05). PFS of low NLR group and low PLR group were longer than those of high NLR group and high PLR group, respectively(P＜0.05). The number of pleural metastases was increased in high NLR and PLR groups(P＜0.05). Cox multivariate analysis showed mGPS was an independent risk prognostic factor for NSCLC(HR=1.962, 95%CI:1.417～2.716, P＜0.05). Conclusion: The mGPS, NLR and PLR were associated with prognosis of NSCLC patients; and mGPS is an independent risk factor for PFS in advanced NSCLC patients.

Received: 03 June 2019

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2019/V29/I05/430

［1］Jomrich G, Hollenstein M, John M, et al. The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction\[J\]. Oncotarget, 2018, 9(6): 6968-6976.
［2］Yu X, Wen Y, Lin Y, et al. The value of preoperative glasgow prognostic score and the Creactive protein to albumin ratio as prognostic factors for longterm survival in pathological T1N0 esophageal squamous cell carcinoma\[J\]. J Cancer, 2018, 9(5):807-815.
［3］Miyamoto R, Inagawa S, Sano N, et al. The neutrophiltolymphocyte ratio (NLR) predicts shortterm and longterm outcomes in gastric cancer patients\[J\]. Eur J Surg Oncol, 2018, 44(5):607-612.
［4］Prabawa IPY, Bhargah A, Liwang F, et al. Pretreatment neutrophiltolymphocyte ratio(NLR) and platelettolymphocyte ratio (PLR) as a predictive value of hematological markers in cervical cancer\[J\]. Asian Pac J Cancer Prev, 2019, 20(3):863-868.
［5］SanchezSalcedo P, deTorres JP, MartinezUrbistondo D, et al. The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development\[J\]. Lung Cancer, 2016, 97:28-34.
［6］Jin J, Hu K, Zhou Y, et al. Prognostic value of the Glasgow prognostic score in lung cancer: evidence from 10 studies\[J\]. Int J Biol Markers, 2018, 33(2):201-207.
［7］Kishiki T, Masaki T, Matsuoka H, et al. Modified glasgow prognostic score in patients with incurable stage Ⅳ colorectal cancer\[J\]. Am J Surg, 2013, 206(2): 234-240.
［8］Aref H, Refaat S. CRP evaluation in nonsmall cell lung cancer\[J\]. Egypt J Chest Dis Tuberc, 2014, 63:717-722.
［9］Ma S, Wang W, Xia B, et al. Multiplexed serum biomarkers for the detection of lung cancer\[J\]. EBioMedicine, 2016, 11:210-218.
［10］Seo SH, Kim SE, Kang YK, et al. Association of nutritional statusrelated indices and chemotherapyinduced adverse events in gastric cancer patients\[J\]. BMC Cancer, 2016, 16(1): 900.
［11］Tsuchihashi K, Ito M, Moriwaki T, et al. Role of predictive value of the modified glasgow prognostic score for laterline chemotherapy in patients with metastatic colorectal cancer\[J\]. Clin Colorectal Cancer, 2018, 17(4): e687-e697.
［12］Fujiwara Y, Haruki K, Shiba H, et al. The comparison of inflammationbased prognostic scores in patients with extrahepatic bile duct cancer after pancreaticoduodenectomy\[J\]. J Surg Res, 2019, 238:102-112.
［13］Arima K, Yamashita YI, Hashimoto D, et al. Clinical usefulness of postoperative creactive protein/albumin ratio in pancreatic ductal adenocarcinoma\[J\]. Am J Surg, 2018, 216(1):111-115.
［14］Kimura S, D′ Andrea D, Soria F, et al. Prognostic value of modified glasgow prognostic score in nonmuscleinvasive bladder cancer\[J\]. Urol Oncol, 2019, 37(3):e19-e28.
［15］Wu CC, Li SH, Lu HI, et al. Inflammationbased prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: a propensity scorematched analysis\[J\]. Peer J, 2018, 6:e5655.
［16］Minami S, Ogata Y, Ihara S, et al. Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer\[J\]. Lung Cancer(Aucki), 2017, 8:249-257.
［17］Minami S, Ihara S, Kim SH, et al. Lymphocyte to monocyte ratio and modified glasgow prognostic score predict prognosis of lung adenocarcinoma without driver mutation\[J\]. World J Oncol,2018,9(1):13-20.
［18］Yotsukura M, Ohtsuka T, Kaseda K, et al. Value of the glasgow prognostic score as a prognostic factor in resectable nonsmall cell lung cancer\[J\]. J Thorac Oncol, 2016, 11(8): 1311-1318.
［19］Graziano V, Grassadonia A, Iezzi L, et al. Combination of peripheral neutrophiltolymphocyte ratio and platelettolymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients\[J\]. Breast, 2019, 44:33-38.
［20］Diem S, Schmid S, Krapf M, et al. NeutrophiltoLymphocyte ratio (NLR) and PlatelettoLymphocyte ratio(PLR) as prognostic markers in patients with nonsmall cell lung cancer (NSCLC) treated with nivolumab\[J\]. Lung Cancer, 2017, 111:176-181.
［21］Jeong UL, Chang DY, Hye SK, et al. Elevated pretreatment platelettolymphocyte ratio is associated with poor survival in stage Ⅳ nonsmall cell lung cancer with malignant pleural effusion\[J\]. SCI REPUK, 2019, 9:4721.
［22］Tang FY, Wang YH, Hemmings BA, et al. PKB/Aktdependent regulation of inflammation in cancer\[J\]. Semin Cancer Biol, 2018, 48(2):62-69.